Jim Cramer shares stock market news about buying Regeneron stock, the Bristol Meyers deal, and Trump’s tweet about a stimulus package.

MyoKardia, Eidos Therapeutics, HMS Holding, Aphria and Jen-Weld are five of Monday's top gainers.

Stocks end higher after President Trump tweets he's leaving Walter Reed Medical Center on Monday evening.

MyoKardia is surging after a takeout deal from Bristol-Myers Squibb, which is marginally higher on the day. Does the deal make Bristol-Myers a buy?

Gilead Sciences is starting the week off with a solid gain. Can bulls take control and drive shares higher?

MydoKardia's experimental heart treatment, Mavacamten, was granted a "breakthrough therapy designation' from the U.S. Food & Drug Administration in July of this year.

Moderna only went public in December, and is already creating a buzz.

Jim Cramer says we actually want some bad news because definitive weaker news now drives stocks up and strong news takes them down.

Jim Cramer looks at the high-flying FANG stocks, and says he likes these companies best when their prices return to earth.

Investors hoping for a revival at the struggling biotech might want to temper their expectations.

Amazon will hold its second Prime sale of the year later this month. Here's how the charts are shaping up now.

In July, Americans perceived that grocery-store inflation totaled an annual rate of 22.8%, well above the actual figure.